Histone deacetylase inhibitors in combinations: Will the preclinical promises be kept?

被引：11

作者：

Bates, Susan E. ^{[1
]}

Piekarz, Richard L. ^{[1
]}

机构：

[1] NCI, Mol Therapeut Sect, Med Oncol Branch, Bethesda, MD 20892 USA

来源：

CANCER JOURNAL | 2007年 / 13卷 / 02期

关键词：

D O I：

10.1097/PPO.0b013e318063bd9f

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：80 / 83

页数：4

相关论文

共 45 条

[1]

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].

Bali, P ;

Pranpat, M ;

Bradner, J ;

Balasis, M ;

Fiskus, W ;

Guo, F ;

Rocha, K ;

Kumaraswamy, S ;

Boyapalle, S ;

Atadja, P ;

Seto, E ;

Bhalla, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26729-26734

[2]

Blagosklonny MV, 2002, MOL CANCER THER, V1, P937

[3]

Blumenschein G, 2004, J CLIN ONCOL, V22, p507S

[4]

Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo [J].

Bruzzese, F ;

Di Gennaro, E ;

Avallone, A ;

Pepe, S ;

Arra, C ;

Caraglia, M ;

Tagliaferri, P ;

Budillon, A .

CLINICAL CANCER RESEARCH, 2006, 12 (02) :617-625

[5]

Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis [J].

Budman, Daniel R. ;

Soong, Richie ;

Calabro, Anthony ;

Tai, Julia ;

Diasio, Robert .

ANTI-CANCER DRUGS, 2006, 17 (08) :921-928

[6]

Burgess AJ, 2001, MOL PHARMACOL, V60, P828

[7]

A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors: a North American brain tumor consortium report [J].

Chang, SM ;

Kuhn, JG ;

Robins, HI ;

Schold, SC ;

Spence, AM ;

Berger, MS ;

Mehta, MP ;

Pollack, I ;

Gilbert, M ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2003, 21 (04) :429-433

[8]

Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American brain tumor consortium report [J].

Chang, SM ;

Kuhn, JG ;

Robins, HI ;

Schold, SC ;

Spence, AM ;

Berger, MS ;

Mehta, MP ;

Bozik, ME ;

Pollack, I ;

Schiff, D ;

Gilbert, M ;

Rankin, C ;

Prados, MD .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :984-990

[9]

Cotreatment with vorinostat (Suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells [J].

Fiskus, Warren ;

Pranpat, Michael ;

Balasis, Maria ;

Bali, Purva ;

Estrella, Veronica ;

Kumaraswamy, Sandhya ;

Rao, Rekha ;

Rocha, Kathy ;

Herger, Bryan ;

Lee, Francis ;

Richon, Victoria ;

Bhalla, Kapil .

CLINICAL CANCER RESEARCH, 2006, 12 (19) :5869-5878

[10]

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells [J].

Fiskus, Warren ;

Pranpat, Michael ;

Bali, Purva ;

Balasis, Maria ;

Kumaraswamy, Sandhya ;

Boyapalle, Sandhya ;

Rocha, Kathy ;

Wu, Jie ;

Giles, Francis ;

Manley, Paul W. ;

Atadja, Peter ;

Bhalla, Kapil .

BLOOD, 2006, 108 (02) :645-652

← 1 2 3 4 5 →